Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metastatic Kidney Cancer of Bad Prognosis
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2016
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms POORTOR
- 08 Jun 2014 Planned number of patients changed from 90 to 92 as reported by ClinicalTrials.gov.
- 08 Jun 2014 Planned End Date changed from 1 Jan 2019 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 05 Jul 2013 New trial record